Algen Biotechnologies

Join Cota Cota Capital Venture Partner Janis Naeve, Ph.D., and Dr. Chun-Hao Huang, Ph.D., Co-Founder and CEO of Algen Biotechnologies tomorrow, Tuesday, June 18, for an insightful webinar on 'Revolutionizing Therapeutic Drug Discovery Through Advanced Gene-Modulation and AI' Register here: https://lnkd.in/gygeyGd7 AI, machine learning (ML), and CRISPR are revolutionizing drug development in the pharmaceutical industry. From 2019 to 2022, over $9 billion was invested in ML-enabled drug discovery start-ups to streamline the R&D process. After his post-doctoral fellowship with Nobel Laureate Dr. Jennifer Doudna, Dr. Chun-Hao Huang founded Algen Biotechnologies. Cota Capital Venture Partner Janis Naeve, Ph.D., and special guest Dr. Chun-Hao Huang, Ph.D., Co-Founder and CEO of Algen Biotechnologies, will discuss how Algen incorporates these advanced technologies to reach scaled causal biology and reverse engineering disease trajectories, aiming to discover novel therapeutics and best-in-class molecules.

I am thrilled to share that Algen Biotechnologies was selected as the honorable mention from a competitive pool of over 150 companies spanning more than 20 countries around the globe at the inaugural J.P. Morgan Asset Management Life Sciences Innovation Summit! Huge thanks to the esteemed, international panel of judges Laurie Glimcher, Yasmine Hayek Kobeissi Ph.D, Anya Schiess, Jorge A. Guzman, MD, MBA, Walid Abbas Zaher MD, PhD, Shahrukh Hashmi for providing insightful feedback on Algen's presentation, as well as Karin Hehenberger, Stephen Squinto, Nabil Kobeissi, Lyfebulb, J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors for organizing the impactful summit. Congrats to all of the finalists - especially my fellow YC founder Rayees R. for being the winner! I would also like to sincerely thank Jennifer Doudna, Frank McCormick, Matthew Rabinowitz, Janis Naeve for their guidance, and the Algen team's great support. Together, we aim to revolutionize therapeutic drug discovery through advanced CRISPR gene-modulation/AI, and develop impactful medicine for patients with unmet medical needs. For more information on this exciting event, please visit

We are excited to share that Algen Biotechnologies was selected as the honorable mention from a competitive pool of over 150 companies spanning more than 20 countries around the globe at the inaugural J.P. Morgan Asset Management Life Sciences Innovation Summit!. It was a great honor to showcase Algen's leading-edge CRISPR gene modulation and AI platform for finding new treatments for cancer, inflammation and metabolic diseases. Huge thanks to the esteemed, international panel of judges and J.P. Morgan Asset Management Life Science Private Capital, Blue Horizon Advisors, Lyfebulb, and the Department of Health Abu Dhabi for hosting this impactful summit. For more information on this exciting event, please visit

Thanks J.P. Morgan Asset Management's Life Sciences Private Capital for selecting Algen Biotechnologies to showcase our advanced CRISPR/AI platform for innovative drug discovery. It's an honor to join preeminent innovators, investors and industry leaders to explore the latest advancements shaping the future of healthcare and improving patient outcomes.

I am thrilled to share that Algen was selected from a competitive pool of over 150 companies spanning more than 20 countries around the globe to showcase our advanced CRISPR/AI platform for innovative drug discovery at the inaugural J.P. Morgan Asset Management Life Sciences Innovation Summit on May 14-15. Looking forward to connecting with preeminent innovators, investors and industry leaders to explore the latest advancements shaping the future of healthcare and improving patient outcomes. For more information on this exciting event, please visit http://spr.ly/6041wkMhF

We are thrilled to share that Algen was selected from a competitive pool of over 150 companies spanning more than 20 countries around the globe to showcase our advanced CRISPR/AI platform for innovative drug discovery at the inaugural J.P. Morgan Asset Management Life Sciences Innovation Summit on May 14-15. Looking forward to connecting with preeminent innovators, investors and industry leaders to explore the latest advancements shaping the future of healthcare and improving patient outcomes. For more information on this exciting event, please visit http://spr.ly/6041wkMhF

We are excited to announce that Algen will be at Biotech Showcase 2024! #BiotechShowcase #JPM2024 Our CEO and Co-Founder, Dr. Chun-Hao Huang, will be presenting our AlgenBrain platform, which combines deep learning and next-generation CRISPR technology to uncover disease-driving RNA messages and enable next-generation therapeutics. Please join us in Room Franciscan-C on Tuesday, Jan 9 at 11:00 AM to learn more. See you there! Yo can also connect with us through the conference portal or reach out via email to meet in person and discuss our cutting-edge technology.